Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT

The board of directors (the "**Board**") of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the "**Company**") announces that Ms. NG Wing Shan ("**Ms. Ng**") has tendered her resignation as the joint company secretary of the Company (the "**Joint Company Secretary**"), an authorized representative of the Company (the "**Authorized Representative**") under Rule 3.05 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and an authorized representative for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "**Process Agent**") with effect from 25 February 2022 due to personal reasons.

Ms. Ng confirmed that she had no disagreement with the Board and there were no matter in respect of her resignation from the positions as the Joint Company Secretary, the Authorized Representative and the Process Agent that need to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board further announces that Mr. WONG Wai Chiu ("**Mr. Wong**") has been appointed as the Joint Company Secretary, an Authorized Representative and the Process Agent in place of Ms. Ng with effect from 25 February 2022. Mr. Peng Qiyun will continue to serve as the other Joint Company Secretary.

The biographical details of Mr. Wong are set out as follows:

Mr. Wong is an associate director of SWCS Corporate Services Group (Hong Kong) Limited. Mr. Wong has extensive experience in compliance and company secretarial work for listed companies.

Mr. Wong is a fellow of the Hong Kong Chartered Governance Institute (formerly known as Hong Kong Institute of Chartered Secretaries), a fellow of the Chartered Governance Institute in the United Kingdom, a member of CPA Australia, a member of the Hong Kong Trustee Association and a Certified Trust Practitioner. Mr. Wong possesses a bachelor degree of social science (Hon.) from the University of Hong Kong, a post-graduate diploma in Hong Kong and United Kingdom laws from the Manchester Metropolitan University in the United Kingdom, a master degree in applied science from the University of Technology, Sydney, Australia, a master degree in corporate governance from the Hong Kong Polytechnic University and a master degree in arbitration and dispute resolution from the City University of Hong Kong.

The Board would like to take this opportunity to express its gratitude to Ms. Ng for her valuable contribution to the Company during her tenure of service and to express its welcome to Mr. Wong on his new appointments.

On behalf of the Board YiChang HEC ChangJiang Pharmaceutical Co., Ltd. TANG Xinfa Chairman

Hubei, the PRC 25 February 2022

As at the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive directors; Mr. TANG Xinfa and Mr. Eddy HUANG as non-executive directors; and Mr. TANG Jianxin, Mr. ZHAO Dayao, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive directors.